VACANCY: FUNDRAISING AND BUSINESS DEVELOPMENT MANAGER

The World Hepatitis Alliance is recruiting for two distinct fundraising functions either as two part-time posts or as one full-time post for the right candidate.

  1. Fundraising and business development manager – corporates and partnerships (.6 FTE)
  2. Fundraising and business development manager: international trusts, foundations and statutory institutions (.4 FTE)

These are both new roles within our organisation, so a pro-active, entrepreneurial approach is a must. You will have the opportunity to shape the fundraising strategy and practice so you can make a big impact from day one.

While you will not have a big fundraising team around you, you will have a highly collaborative and supportive staff team who are totally committed to supporting your success.

The World Hepatitis Alliance drives the global fight against viral hepatitis, one of the leading causes of death worldwide. We amplify the voices of people living with viral hepatitis to drive action to make the elimination of viral hepatitis a reality by 2030. We are guided by our shared values of making a difference, trust, integrity and ambition – all of which makes our organisation an exciting and fulfilling place to work for.

Diversity and inclusion are at the heart of our work as a global organisation. We aim for our staff team to reflect the diverse communities we serve.

Please apply using the application form and job descriptions provided, please note that job descriptions for both roles are contained in the document avaliable below. Please indicate if you are applying for one or both roles. International applicants welcome.

Deadline: 12noon GMT, Friday 4 December

First interviews: starting 8 December

Second interviews:  week of 14 December

Start date: January 2020

To apply please read the job description which can be downloaded here please note the job descriptions for both roles are in the same document.

Once you have read the job description, please complete an application form which can be downloaded here and send together with a completed equality and diversity monitoring form to admin@worldhepatitisalliance.org 

 

 

Latest News

Sign up to receive updates from WHA

Name(Required)
I would like to hear about(Required)

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Hepatitis and PWID/harm reduction 

 

11:35 – 11:40  

Chair: WHO – Intro and set the scene.  

 

11:40 – 11:55  

Co-chair:  EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe. 

 

11:55 – 12:00 

ID 29: Ema Pos (not yet registered) 

Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation. 

 

12:05 – 12:10  

ID 152: Brian Conway (Registered in person) 

Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.

 

12:10 – 12:15 

ID 212: Jasmine West (not yet registered) 

Title: From lived experience to lived expertise: a syndemic approach. 

 

12:15 – 12:20 

ID: 299 Mercy Nyakowa (Registered in person) 

Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya 

 

12:20 – 12:25 

ID: 133 Nalinikanta Rajkumar (Registered in person) 

Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?  

 

12:25 – 12:30 

Q&A and closing remarks   

tHIS

 

IS 

 

BEN’S

 

 

 

BIG 

 

 

TEST

effective case finding strategies

Supported by Vir Biotechnology, Inc

During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.

Session Agenda

14:40 – 14:45    

Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)

14:45 – 15:05   

Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology

15:05 – 15:10    

Final remarks and close